連往主要內容區塊
:::
:::
蔡正華 / John Tsai
蔡正華 / John Tsai
Personal Webpage
Professional Experience
- Executive Partner, Syncona Venture Capital (London UK), 2023/5-Present
- President, Global Drug Development and Chief Medical Officer, Novartis AG (Basel, CH), 2018/5-2023/5
- Chief Medical Officer and Senior Vice President Medical Affairs, Amgen (Thousand Oaks, CA USA), 2017/5-2018/5
- Head of Late Phase Development and Oncology Development Leader, Bristol Myers Squibb (Princeton, NJ USA), 2015/10-2017/5
- Head of Worldwide Medical Affairs, Bristol Myers Squibb (Princeton, NJ), 2014/5-2015/10
- Chief Medical Officer Europe, Bristol Myers Squibb (Paris, France), 2012/10-2014/5
- Head of US Medical, Bristol Myers Squibb (Plainsboro, NJ), 2010/1- 2012/10
- Vice-President, Cardiovascular and Metabolics Disease Area, Bristol Myers Squibb (Plainsboro, NJ), 2006/8-2010/1
- Senior Director, Atherosclerosis Group Leader and Full Development Team Leader, PFIZER INC., New York, NY, 2003/11-2006/8
- Medical Director, Lipitor and Norvasc Clinical Teams, PFIZER INC., New York, NY, 2001/6-2003/11
- Hospital Based Physician – Internal Medicine Faculty & Chief Resident, KAISER PERMANENTE HOSPITAL, San Francisco, CA, 1997/6- 2001/6
- Lead Project Engineer & International Marketing Liaison, GE APPLIANCES, Louisville, KY, 1991/9-1993/8
- Supervisor, Computed Tomography (CT) Scanner Manufacturing, GE & YOKOGAWA MEDICAL SYSTEMS, Milwaukee, WI & Tokyo (1988/12-1991/9)
Education
- California Licensed Internal Medicine Physician
- Residency in Kaiser Foundation Hospitals, San Francisco, California (Specialty: Internal Medicine)
- M.D. in University of Louisville School of Medicine, Louisville, Kentucky
- B.S.E.E. in Washington University, St. Louis, Missouri (Major: Electrical Engineering)
Board Membership
- Independent board Director, Blueprint Medicines, 2023/1-present
- Chair and Executive Director, Forcefield Therapeutics, 2023/5-present
- Member, Genomics Institute of the Novartis Research Foundation, 2018/5-2022/5
- Non-Executive Director, Novartis Venture Fund, 2018/5-2022/5
